A new study in the September issue of the Journal of Clinical Investigation by Jeremy Graff and colleagues from Eli Lilly and Company demonstrates the anti-cancer effect of a new therapeutic (eIF4E-specific anti-sense oligonucleotides) in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers.
Post new comment